BGB-283, also known as Beigene-283 or Lifirafenib, is a Novel potent and selective RAF Kinase and EGFR inhibitor. BGB-283-displays Potent Antitumor Activity in B-RAF Mutated Colorectal Cancers.
For research use only. We do not sell to patients.
Name | BGB-283 |
---|---|
Synonyms | BGB-283; BGB 283; BGB283; Beigene-283; Beigene283; Beigene 283; Lifirafenib |
Molecular Formula | C25H17F3N4O3 |
Molecular Weight | 478.43 |
Smile | [H][C@@]1(C2=CC(OC3=C(CCC4=O)C(N4)=NC=C3)=CC=C2O[C@]51[H])[C@@H]5C6=NC7=CC=C(C=C7N6)C(F)(F)F |
InChiKey | NGFFVZQXSRKHBM-FSSWDIPSSA-N |
InChi | InChI=1S/C25H17F3N4O3/c26-25(27,28)11-1-4-15-16(9-11)31-24(30-15)21-20-14-10-12(2-5-17(14)35-22(20)21)34-18-7-8-29-23-13(18)3-6-19(33)32-23/h1-2,4-5,7-10,20-22H,3,6H2,(H,30,31)(H,29,32,33)/t20-,21+,22+/m1/s1 |
CAS Number | 1446090-77-2;1446090-79-4 |
Related CAS |
Packaging | Price | Availability | Purity | Shipping Time |
---|---|---|---|---|
Bulk | Enquiry | Enquiry | Enquiry |
Formulation | off-white solid |
---|---|
Purity | >98% |
Storage | 3 years -20ºCpowder |
Solubility | Soluble in DMSO, not in water |
Handling | |
Shipping Condition | Shipped under ambient temperature |
HS Code |
Targets | |
---|---|
Mechanism | |
Cell study | |
Animal study | |
Clinical study |